NanoViricides, Inc. (NYSE: $NNVC), a clinical-stage company specializing in innovative nanomaterials for antiviral therapy, is making significant strides in the regulatory development of its lead drug candidate, NV-387.
Read more:
https://tinyurl.com/3htrdcr2